JP2011504092A5 - - Google Patents

Download PDF

Info

Publication number
JP2011504092A5
JP2011504092A5 JP2010530629A JP2010530629A JP2011504092A5 JP 2011504092 A5 JP2011504092 A5 JP 2011504092A5 JP 2010530629 A JP2010530629 A JP 2010530629A JP 2010530629 A JP2010530629 A JP 2010530629A JP 2011504092 A5 JP2011504092 A5 JP 2011504092A5
Authority
JP
Japan
Prior art keywords
vegf
antibody
composition
fragment
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010530629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2008/001410 external-priority patent/WO2009053987A1/en
Publication of JP2011504092A publication Critical patent/JP2011504092A/ja
Publication of JP2011504092A5 publication Critical patent/JP2011504092A5/ja
Pending legal-status Critical Current

Links

JP2010530629A 2007-10-25 2008-10-26 血管内皮増殖因子(vegf)の血管新生誘発性アイソフォームに特異的な抗体 Pending JP2011504092A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98243807P 2007-10-25 2007-10-25
PCT/IL2008/001410 WO2009053987A1 (en) 2007-10-25 2008-10-26 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)

Publications (2)

Publication Number Publication Date
JP2011504092A JP2011504092A (ja) 2011-02-03
JP2011504092A5 true JP2011504092A5 (https=) 2012-11-15

Family

ID=40385456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530629A Pending JP2011504092A (ja) 2007-10-25 2008-10-26 血管内皮増殖因子(vegf)の血管新生誘発性アイソフォームに特異的な抗体

Country Status (7)

Country Link
US (1) US8592563B2 (https=)
EP (1) EP2203480A1 (https=)
JP (1) JP2011504092A (https=)
CN (1) CN101970486A (https=)
AU (1) AU2008315414A1 (https=)
CA (1) CA2703154A1 (https=)
WO (1) WO2009053987A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
US20130034861A1 (en) * 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CA2837914A1 (en) * 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
WO2014117053A1 (en) * 2013-01-27 2014-07-31 The Cleveland Clinic Foundation Anti-angiogenic vegf-ax isoform
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
JP6675687B2 (ja) * 2015-05-29 2020-04-01 国立大学法人名古屋大学 尿中VEGF−A165bを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US7820178B2 (en) * 2001-08-01 2010-10-26 University of Brisol VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
US20050009110A1 (en) 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
AU2006242449A1 (en) * 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. VEGF variants
US20080031815A1 (en) * 2006-07-27 2008-02-07 Xiaoyuan Chen Pet imaging of vascular endothelial growth factor receptor (VEGFR), compositions for VEGF cancer imaging, and methods of VEGF cancer imaging
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments

Similar Documents

Publication Publication Date Title
JP2011504092A5 (https=)
DK2888283T3 (en) ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
EP3381940B1 (en) Anti-ang2 antibody
DK2580240T3 (en) S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF
CN102741292B (zh) 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体
EA031043B1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
JPWO2005028515A1 (ja) ヒトインスリン様成長因子に対する遺伝子組換え抗体
EA036698B1 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
CN112955748A (zh) 治疗癌症的方法
KR102715157B1 (ko) Il-17c에 대한 항체
JP2010527939A5 (https=)
WO2018031865A1 (en) Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
CN105849125B (zh) 神经调节蛋白变构抗her3抗体
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
KR20210126057A (ko) 암세포에 존재하는 케라틴 14(krt14)의 세포외 부분을 표적화함으로써 암을 치료하거나 예방하는 방법
WO2014175444A1 (ja) 抗nlrr1抗体
JP2022502434A (ja) がんの治療用の薬学的組合せ
US10393748B2 (en) Method for predicting efficacy of c-Met inhibitor
US20170137523A1 (en) Therapy for gist
KR102926992B1 (ko) Tctp에 특이적으로 결합하는 항체 및 이의 용도
US10472682B2 (en) Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF
CN120035606A (zh) 一种治疗实体瘤的方法
WO2025255282A1 (en) Anti-cdh17 binding molecules
WO2023089131A1 (en) Treatment and diagnosis of diseases associated to pathogenic fibrosis